The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula I

QA.sub.aB.sub.bC.sub.c(I)

where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a+b+c is 1, 2, 3, 4 or 6
where
A is a group

##STR00001##

B is a group

##STR00002##

C is a group

##STR00003##

where # denotes the point of attachment to Q; X is S or NR.sup.14 and Q, R.sup.1, R.sup.2, R.sup.3 and R.sup.14 are as defined in claim 1 and in the description.

The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.

The present invention relates to a polymerizable composition comprising at least one ethylenically unsaturated, polymerizable compound and at least one oxime sulfonate compound of the formula I

QA.sub.aB.sub.bC.sub.c(I)

where a is 0, 1, 2, 3, 4 or 6, b is 0, 1, 2, 3, 4 or 6, and c is 0, 1, 2, 3, 4 or 6, where the sum of a+b+c is 1, 2, 3, 4 or 6
where
A is a group

##STR00001##

B is a group

##STR00002##

C is a group

##STR00003##

where # denotes the point of attachment to Q; X is S or NR.sup.14 and Q, R.sup.1, R.sup.2, R.sup.3 and R.sup.14 are as defined in claim 1 and in the description.

The present invention also relates to the use of the this composition, to novel oxime sulfonates and the use of the oxime sulfonates as thermal curing promoter.

An electrolyte containing a solvent including at least one compounds of formula I, wherein A.sub.1 is an oxygen atom or a single bond, A.sub.2 is a single bond or CHR.sub.4, R.sub.1 and R.sub.2 are each independently a hydrogen atom, C1-6 alkyls or a C1-6 fluoroalkyls, R.sub.3 and R.sub.4 are each independently a hydrogen atom, a fluorine atom, C1-6 alkyls or C1-6 fluoroalkyls, A1 and A2 cannot both be single bonds simultaneously, and only one of R.sub.1 to R.sub.4 includes a fluorine atom is described. The electrolyte can make a metal negative electrode secondary battery have good cycling performance and good discharge capacity retention at low temperature.

##STR00001##

An electrolyte containing a solvent including at least one compounds of formula I, wherein A.sub.1 is an oxygen atom or a single bond, A.sub.2 is a single bond or CHR.sub.4, R.sub.1 and R.sub.2 are each independently a hydrogen atom, C1-6 alkyls or a C1-6 fluoroalkyls, R.sub.3 and R.sub.4 are each independently a hydrogen atom, a fluorine atom, C1-6 alkyls or C1-6 fluoroalkyls, A1 and A2 cannot both be single bonds simultaneously, and only one of R.sub.1 to R.sub.4 includes a fluorine atom is described. The electrolyte can make a metal negative electrode secondary battery have good cycling performance and good discharge capacity retention at low temperature.

##STR00001##

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions in which interleukin 1? activity is implicated. ##STR00001##

Provided herein are halogenated ether compounds of Formula (I), Formula (II), or Formula (III):

##STR00001##

Also provided are electrolytes comprising one or more compounds of Formula (I), Formula (II), or Formula (III) and electrochemical cells comprising electrolytes comprising one or more compounds of Formula (I), Formula (II), or Formula (III).

Provided herein are halogenated ether compounds of Formula (I), Formula (II), or Formula (III):

##STR00001##

Also provided are electrolytes comprising one or more compounds of Formula (I), Formula (II), or Formula (III) and electrochemical cells comprising electrolytes comprising one or more compounds of Formula (I), Formula (II), or Formula (III).

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.